Barclays initiates with Overweight rating: Intellia Therapeutics (NASDAQ:NTLA), Editas Medicine (NASDAQ:EDIT), CRISPR Therapeutics (NASDAQ:CRSP), Alnylam Pharmaceuticals (NASDAQ:ALNY), bluebird bio (NASDAQ:BLUE), AveXis (NASDAQ:AVXS), Juno Therapeutics (NASDAQ:JUNO), Puma Biotechnology (NYSE:PBYI).
aTyr Pharma (NASDAQ:LIFE) initiated with Overweight rating and $7 (150% upside) price target by Piper Jaffray.
Perrigo (NASDAQ:PRGO) initiated with Outperform rating and $88 (13% upside) price target by Oppenheimer citing stabilization of the business and encouraging product launches.
Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Market Perform rating by Oppenheimer citing competitive headwinds, full valuation and the need for further clarity related to Exparel growth drivers and bupivacaine programs.
AstraZeneca (NYSE:AZN) initiated with Outperform rating and $38 (25% upside) price target by BMO Capital Markets.
Achaogen (NASDAQ:AKAO) initiated with Sell rating and $9 (49% downside risk) price target by Empire. Shares are down 4%.
NuVasive (NASDAQ:NUVA) initiated with a Buy rating and $82 (34% upside) price target by BTIG Research.
Globus Medical (NYSE:GMED) initiated with Buy rating and $37 (23% upside) price target by BTIG Research.
Aptose Biosciences (NASDAQ:APTO) upgraded to Buy with a $4 (167% upside) price target by H.C. Wainwright.
Varian Medical Systems (NYSE:VAR) downgraded to Neutral by BTIG Research.
Now read: Perrigo: Finally A Turning Point? »
Subscribe for full text news in your inbox